Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD7442 in Healthy Chinese Adults

NCT05437289 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05437289
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05437289 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD7442 in Healthy Chinese Adults
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
October 9, 2021
Completion date
January 16, 2023
Enrollment
61 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus disease 2019 (covid-19), healthy volunteer